Humacyte, Inc. Files 8-K: Material Agreement and Exhibits

Ticker: HUMA · Form: 8-K · Filed: Apr 24, 2026 · CIK: 0001818382

Sentiment: neutral

Topics: material-agreement, filing, exhibits

TL;DR

Humacyte signed a big deal, check the exhibits for deets.

AI Summary

On April 21, 2026, Humacyte, Inc. entered into a material definitive agreement, as detailed in Item 1.01 of their 8-K filing. The filing also includes Regulation FD disclosures and financial exhibits, as noted in Items 7.01 and 9.01 respectively. The company is located at 2525 East North Carolina Highway 54, Durham, NC 27713.

Why It Matters

This filing indicates Humacyte has entered into a significant new agreement, which could impact its business operations and future financial performance.

Risk Assessment

Risk Level: medium — Entering into material definitive agreements can introduce new risks and opportunities that are not yet fully understood.

Key Numbers

Key Players & Entities

FAQ

What is the nature of the material definitive agreement entered into by Humacyte, Inc. on April 21, 2026?

The filing indicates the entry into a material definitive agreement under Item 1.01, but the specific details are likely within Exhibit 10.1.

What information is provided in Exhibit 99.1 of the filing?

Exhibit 99.1 is listed as 'EX-99.1' and is associated with Regulation FD Disclosure (Item 7.01).

When was this 8-K filing accepted by the SEC?

The filing was accepted on April 24, 2026.

What is Humacyte, Inc.'s business address?

Humacyte, Inc.'s business address is 2525 East North Carolina Highway 54, Durham, NC 27713.

What SIC code is associated with Humacyte, Inc.?

The SIC code associated with Humacyte, Inc. is 2836, which pertains to Biological Products, (No Diagnostic Substances).

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 24, 2026 regarding Humacyte, Inc. (HUMA).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing